BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//InBio - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://inbio.com
X-WR-CALDESC:Events for InBio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260218T110000
DTEND;TZID=America/New_York:20260218T120000
DTSTAMP:20260409T051156
CREATED:20260128T193354Z
LAST-MODIFIED:20260220T185611Z
UID:3029-1771412400-1771416000@inbio.com
SUMMARY:InBio Webinar: Latest Innovations in Basophil Activation Testing for Food Allergy Investigation
DESCRIPTION:BAT Webinar – ON DEMAND \nLatest Innovations in Basophil Activation Testing for Food Allergy Investigation \n \nWATCH ON DEMAND HERE \nInBio is teaming up with Beckman Coulter to bring you a webinar on Wednesday\, February 18th that will explore how next-generation basophil activation testing can simplify workflows\, improve reproducibility and overcome common bottlenecks in food allergy research. \nThe webinar will discuss how Beckman Coulter’s streamlined\, robust\, and easy-to-use Basophil Activation Test (BAT)—leveraging innovative dry technology and InBio’s high quality food protein standards—is designed to overcome traditional limitations in allergy testing. \n  \nWhat’s on the Agenda \nExplore technical advances in BAT for simplified implementation \nUnderstand how food protein standards are manufactured with defined allergen composition \nLearn validation processes that ensure reproducibility and reliability \nDiscuss how molecular approaches can improve allergy platforms \n  \nThe webinar is available on-demandm\, watch here. \nSpeakers\n \n  \nSabina Wuenschmann\, PhD\, is Vice President of Allergen Manufacturing and R&D at InBio\, where she has led scientific innovation and product development for over 15 years. Her career spans virology research\, allergen molecular research\, and proteomics with a strong focus on translating science into high-quality commercial solutions for global diagnostic and research markets. Research made real! \n  \nJean-Marc Busnel\, PhD is head of the Translational Research Team of Beckman Coulter Life Sciences and co-author of more than 55 peer-reviewed articles in the fields of bioanalytical chemistry\, metabolomics\, proteomics and whole blood based functional flow cytometry assays. Dr. Busnel works on further leveraging the capabilities of Flow Cytometry for patient stratification in various pathological areas such as allergy\, autoimmunity\, infectious diseases and oncology. \n  \nFind full bios and more details on the webinar here.  \n  \nCan’t attend live? Register here and we will send you a recording after the webinar to all registrants.  Hope to see you there!
URL:https://inbio.com/event/inbio-webinar-latest-innovations-in-basophil-activation-testing-for-food-allergy-investigation/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231102T100000
DTEND;TZID=America/New_York:20231102T110000
DTSTAMP:20260409T051156
CREATED:20231011T143852Z
LAST-MODIFIED:20231011T153138Z
UID:1814-1698919200-1698922800@inbio.com
SUMMARY:InBio Webinar: Food Allergy Diagnostics- Reducing Uncertainty
DESCRIPTION:Food Allergy Diagnostics- Reducing Uncertainty 02 Nov 2023\nRegister here \nRecent reports of false negative reactions upon skin testing with diagnostic food allergens raise serious concerns for food allergic patients and their health care providers. In December 2022\, ALK-Abelló\, the world’s largest allergen manufacturer\, voluntarily recalled 4 lots of peanut extract that gave false negative reactions on skin testing and were associated with adverse events\, including life-threatening anaphylaxis. In March\, the U.S. Food and Drug Administration introduced safety labeling changes for all diagnostic food allergenic extracts including a Warning of anaphylaxis following false negative skin tests. \nThe FDA Warning proved to be profound. In September\, ALK-Abelló voluntarily withdrew one lot of diagnostic pecan extract following false negative skin test results associated with adverse events including one case of life-threatening anaphylaxis. \nCollaborative studies with Drs. Cosby Stone and Scott Smith (Vanderbilt University) and Jonathan Hemler (University of Virginia) showed significant differences between recall and non-recall lots of the diagnostic peanut extracts. The recall lots contained negligible amounts of major peanut allergens by either InBio murine mAb ELISA or using human IgE mAb ELISA. These studies underscore the value of measuring specific allergens for quality control and standardization purposes. \nThere is an urgent need for standardization of food allergen extracts. Over the past 25 years\, InBio has developed a multi-faceted approach to allergen standardization which includes biochemical methods\, immunoassays\, mass spectrometry and human IgE monoclonal antibodies. \nJoin InBio scientists to discuss the food allergen recalls\, as well as recent advances in molecular diagnostics and standardization on Thursday\, November 2nd at 10am EDT. Register here. \nSpeakers\n \nLearning Objectives: \n\nUnderstand the significance behind the food extract recalls.\nUnderstand the multi-faceted approach in allergen standardization.\nDiscuss the latest research on InBio’s exclusive product\, human IgE monoclonal antibodies.\n\nWhen: Thursday\, November 2nd\, 2023 10am EDT. \nWe hope that you can join us and attend the webinar. There will be plenty of opportunity for discussion in the Q&A. Please contact Beattie Sturgill with any questions or comments. Register here.
URL:https://inbio.com/event/inbio-webinar-food-allergy-diagnostics/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230531T100000
DTEND;TZID=America/New_York:20230531T110000
DTSTAMP:20260409T051156
CREATED:20230512T171524Z
LAST-MODIFIED:20230512T171605Z
UID:1361-1685527200-1685530800@inbio.com
SUMMARY:InBio Webinar- Molecular Allergy Diagnostics: Innovative Products and Resources
DESCRIPTION:InBio Webinar- Molecular Allergy Diagnostics: Innovative Products and Resources 31 May 2023\nInBio has served the allergen diagnostic industry for over 10 years. Using our proven expertise in proteomics\, InBio has designed and created a comprehensive portfolio of allergen components for diagnostic use\, including food\, dust mite\, animal\, mold\, pollen\, cockroach\, venom and other allergens. \nIn addition\, InBio has a unique portfolio of Human IgE Monoclonal Antibodies (hIgE mAb) to a diverse panel of clinically important allergens. The hIgE mAb are derived from patients with a clinical history of allergic disease and are poised to make a significant impact on research and diagnostic applications. \nJoin InBio scientists\, together with our guest speaker Dr. Lorenz Aglas\, to discuss these molecular allergy diagnostic tools and more in an interactive webinar on Wednesday\, May 31st   at 10am EDT.  Dr. Aglas will present his recent work using hIgE mAb to initiate mediator release from huRBL cells. Register here.
URL:https://inbio.com/event/inbio-webinar-molecular-allergy-diagnostics-innovative-products-and-resources/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230418T100000
DTEND;TZID=America/New_York:20230418T110000
DTSTAMP:20260409T051156
CREATED:20230330T143414Z
LAST-MODIFIED:20230330T143516Z
UID:1227-1681812000-1681815600@inbio.com
SUMMARY:InBio Webinar- Cleaning and Consumer Product Testing Capabilities
DESCRIPTION:InBio Webinar- Cleaning and Consumer Product Testing Capabilities 18 April 2023\nInBio has essential tools and unmatched allergen testing expertise to help cleaning and consumer product companies validate allergen removal claims. \nJoin InBio scientists to discuss details of these products and technologies on our latest webinar on Tuesday\, April 18th at 10am EDT. \nDetails of the webinar and registration (required) below\, while recordings of our other webinars can be found here.
URL:https://inbio.com/event/inbio-webinar-cleaning-and-consumer-product-testing-capabilities/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211208T110000
DTEND;TZID=America/New_York:20211208T120000
DTSTAMP:20260409T051156
CREATED:20221108T150332Z
LAST-MODIFIED:20221108T153451Z
UID:534-1638961200-1638964800@inbio.com
SUMMARY:CRISPR Cat Webinar
DESCRIPTION:Gene Editing of the Major Cat Allergen\, Fel d 1\nIndoor Biotechnologies is applying CRISPR gene editing to delete Fel d 1 from cat cells\, an approach to creating a hypoallergenic cat. Join Indoor Biotechnologies scientists to discuss details of the CRISPR Cat project on the holiday edition of our webinar series on Wednesday\, December 8th at 11am EST. \nIndoor Biotechnologies scientists are investigating the role of Fel d 1 across all cats\, both domesticated and wild. Fel d 1 is the cat allergen of choice as it accounts for 60-90% of anti-cat IgE. Significant research has been conducted at Indoor Biotechnologies to identify conserved regions of the Fel d 1 genes and to delete Fel d 1 from feline cells using CRISPR as an approach that could ultimately be used to generate Fel d 1-free cats.\nThe webinar will cover CRISPR Cat in detail\, providing the origins\, technical background\, data\, and future goals of the project. \nLearning Objectives:\n\nLearn more on the history of CRISPR Cat\, including how the gene for Fel d 1 was first isolated.\nLearn more about CRISPR Cat milestones to date\, including the development\, methods\, and results.\nUnderstand the importance of CRISPR Cat\, and how the project may have larger implications on the application of CRISPR technology in allergy.
URL:https://inbio.com/event/crispr-cat-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211027T110000
DTEND;TZID=America/New_York:20211027T120000
DTSTAMP:20260409T051156
CREATED:20221108T150031Z
LAST-MODIFIED:20221108T153413Z
UID:533-1635332400-1635336000@inbio.com
SUMMARY:SARS-CoV-2 Proteins and Simple T Cell Test Webinar
DESCRIPTION:SARS-CoV-2 Proteins and Simple T cell Test: Essential Tools for COVID-19 Research and Development\nIndoor Biotechnologies has a suite of SARS-CoV-2 proteins in various expression systems\, as well as a rapid whole blood T cell test in development. Join Indoor Biotechnologies scientists to discuss details of these products and technologies on our latest webinar on Wednesday\, October 27th at 11am EDT. \nIndoor Biotechnologies has used its proven expertise in structural biology\, protein expression and purification to manufacture a suite of recombinant SARS-CoV-2 proteins\, including a full-length spike protein. These proteins have been engineered\, optimized and expressed in both mammalian and bacterial expression systems. \nInBio® SARS-CoV-2 proteins are validated for purity by LC-MS/MS\, and their IgG reactivity tested using COVID-19 positive patients’ sera by ELISA. These proteins are manufactured under an ISO 9001:2015 certified Quality Management System. \nIndoor Biotechnologies has developed a rapid whole blood T cell test as part of an Innovate UK grant for assessment of vaccine or viral induced T cell response to SARS-CoV-2. Individuals exposed to SARS-CoV-2 may not produce long-lasting protective antibodies. T cell assays may be an important complement to COVID-19 diagnostic testing and vaccine development. \nInitial trials from InBio® show that the T cell test correlates with PCR and antibody responses and that the test can be used to monitor changes in T cell responses after vaccination. \nPreviously\, virus specific T cell tests have been difficult to standardize and require specific knowledge/equipment\, which presents a significant barrier for large scale\, effective testing. The InBio® simple T cell test aims to break these barriers and is being  optimized for easy implementation\, enabling high throughput testing of COVID-19 T cell immunity. \nThe webinar will cover these products in detail\, providing technical background\, data\, and applications. \nLearning Objectives:\n\nLearn more on the available suite of SARS-CoV-2 proteins\, including ELISA data comparing SARS-CoV-2 nucleocapsid RNA binding domain vs full-length spike proteins in determining vaccine efficiency.\nLearn more about the InBio® simple T cell test\, including the development\, milestones\, and future goals.\nUnderstand how Indoor Biotechnologies’ SARS-CoV-2 resources can aid in COVID-19 research\, diagnostics\, and vaccine efforts.
URL:https://inbio.com/event/sars-cov-2-proteins-and-simple-t-cell-test-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210629T110000
DTEND;TZID=America/New_York:20210629T120000
DTSTAMP:20260409T051156
CREATED:20221108T145517Z
LAST-MODIFIED:20221108T153300Z
UID:532-1624964400-1624968000@inbio.com
SUMMARY:Environmental Testing Suite and Viral Testing Webinar
DESCRIPTION:Environmental Testing Suite and Viral Testing: Use in Product Development and Validation\nIndoor Biotechnologies offers a broad range of product testing services\, including the Environmental Testing Suite and viral testing capabilities in accordance with applicable standards. \nIndoor Biotechnologies has recently expanded facilities and commissioned a new and improved Environmental Testing Suite (ETS) in Cardiff\, Wales. The suite is primarily used to test the safety and efficacy of home and personal care products including air purification devices\, cleaning products\, vacuum cleaners\, carpets and textiles. The facility supports all stages of product development\, from R&D\, to formulation testing and validation of end-product claims. Comprehensive allergen testing is provided onsite. \nAdditionally\, Indoor Biotechnologies offers viral testing services\, including virucidal activity and assessments of virus viability on surfaces and in suspension. Custom testing methods can be designed to test a variety of products for virucidal efficacy\, including Vaccinia virus and Human Coronavirus 229E which can support product claims against coronaviruses\, including SARS-CoV-2. Indoor Biotechnologies laboratories in the UK have tissue culture facilities that operate under Biosafety Level 2 and are ISO 17025 compliant. Utilizing the unique setup of the ETS\, Indoor Biotechnologies are also developing models for viral aerosol studies\, which can be customized to test the safety and efficacy of a range of anti-viral products against airborne viruses. \nLearning Objectives:\n\nLearn more about the ETS and its technical specifications.\nLearn more on Indoor Biotechnologies’ expertise in viral immunology and testing capabilities.\nUnderstand how the ETS and viral testing can help develop\, improve\, and validate products.
URL:https://inbio.com/event/environmental-testing-suite-and-viral-testing-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210421T110000
DTEND;TZID=America/New_York:20210421T120000
DTSTAMP:20260409T051156
CREATED:20221108T145117Z
LAST-MODIFIED:20221108T153104Z
UID:530-1619002800-1619006400@inbio.com
SUMMARY:Molecular Approach to Allergy Diagnostics Webinar
DESCRIPTION:Molecular Approach to Allergy Diagnostics: Innovative Products and Services\nIndoor Biotechnologies has served the allergy diagnostic industry for over 10 years. Using our proven expertise in structural biology and protein expression\, Indoor Biotechnologies has designed and created a comprehensive portfolio of allergen components for diagnostic use\, including dust mite\, animal\, food\, mold\, pollen\, cockroach\, venom and other allergens. \nIn addition\, Indoor Biotechnologies has recently licensed a unique portfolio of Human IgE Monoclonal Antibodies to a diverse panel of clinically important allergens. This technological breakthrough is poised to make a significant impact on diagnostic applications. The human IgE monoclonal antibodies are derived from patients with a clinical history of allergic disease and an excellent alternative to allergic-sera for diagnostic purposes. \nLearning Objectives:\n\nUnderstand the manufacturing and quality benefits of Indoor Biotechnologies’ purified allergens.\nUnderstand the science behind the unique and exclusive Human IgE mAb and the significant impact that they can have in allergy diagnostics.\nUnderstand how Indoor Biotechnologies’ molecular approach to allergy diagnostics can improve new and existing diagnostic platforms.
URL:https://inbio.com/event/molecular-approach-to-allergy-diagnostics-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210303T110000
DTEND;TZID=America/New_York:20210303T120000
DTSTAMP:20260409T051156
CREATED:20210224T205845Z
LAST-MODIFIED:20221108T153146Z
UID:392-1614769200-1614772800@inbio.com
SUMMARY:Allergen Variability in Early Introduction Foods Webinar
DESCRIPTION:Allergen Variability in Early Introduction Foods: What Have We Learned?\nInBio has completed a study comparing the allergen content of early introduction food (EIF) brands. This study demonstrated significant variability in the allergen concentration and dose in EIF from 9 manufacturers\, when tested for 17 major allergens. \nTopic:\nUse of MARIA® for Foods to Compare the Allergen Content of Early Introduction Food (EIF) Brands \nDescription:\nInBio’s has further developed its multiplex technology\, MARIA® for Foods\, to simultaneously measure up to 17 major food allergens from a single sample. This state-of-the-art technology was recently used to compare specific food allergen levels in EIF brands\, as reported at the AAAAI annual meeting. The study demonstrated significant variability in the allergen concentration and dose in EIF from nine manufacturers\, when tested for 17 major allergens. \nLearning Objectives:\n\nUnderstand the applications of MARIA® for Foods for measuring specific food allergens\nDiscuss details\, data\, and impact of the EIF study\nUnderstand how Indoor Biotechnologies’ molecular approach to food allergy can improve the quality of EIF and other therapeutic products for food allergy\n\nWho Should Attend:\nAllergists\, Pediatricians\, Health Care Providers\, Food Advocacy and Food Safety Organizations\, Food Industries\, Food Immunotherapy and Diagnostic Companies\, Food Allergen Researchers\, Regulatory Authorities\, Investors\, Consumers and Food Allergy Sufferers.
URL:https://inbio.com/event/allergen-variability-in-early-introduction-foods-webinar/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR